About this archive.

What this site is

Doctor GHK-Cu is a darkroom for the peer-reviewed literature on GHK-Cu, the copper-tripeptide complex first isolated from human plasma by Loren Pickart in the early 1970s. The archive runs from the foundational 1988 Maquart fibroblast paper to the 2025 liposomal-delivery and comprehensive tripeptide reviews — a fifty-year roll of frames, slowly developed.

The register is archivist rather than clinician. Each page is summarized from named, dated, citable papers. Each numbered chip in the body links back to the entry on /references. Where the literature is thin, the page says so; where the magnitude claims rest on single-platform microarray data rather than independent replication, the page says that too. The site is small and the topic is narrow; both are deliberate.

What this site is not

No clinic stands behind the darkroom. No one here is a clinician, nothing on these pages is medical advice, and there is no product to manufacture, stock, or sell — the work is a reading of published science and nothing besides.

The word 'Doctor' in the domain is a stance toward the literature, not a claim about services — the position the publisher takes relative to the record. Read it as 'archivist of record' or 'darkroom curator,' not as treating physician. There are no patients here, no consultation service, and no prescription pathway, and nothing on this site urges anyone to obtain or use GHK-Cu. Topical Copper Tripeptide-1 is a widely marketed cosmetic ingredient; non-topical and systemic uses of GHK-Cu are not approved by any regulatory authority and remain experimental. This archive describes what the literature has studied — the route, the dose, the model, the outcome. What readers do with that information is their own business, not ours.

Sourcing and editorial method

The archive draws on PubMed, PubMed Central, the original publishers' open-access archives, and a small number of industry-published cosmetic-dermatology sources where the underlying study is identifiable and traceable. Every number on the site traces to a real paper; any claim that cannot is removed or marked as descriptive. Where two papers disagree, both are cited. Where a number is widely circulated but lightly sourced (the '4,000 genes' framing, for instance), the page notes the caveat.

We do not interview subjects, run our own assays, or publish primary research. The contribution is curatorial and editorial: the literature is large, scattered across cosmetic and biomedical journals, and dominated by one research group's review papers. Setting it out in chronological frames with dose, species, route, and citation attached is what this site is for.

Regulatory framing

GHK-Cu is recognized as a cosmetic ingredient (INCI: Copper Tripeptide-1) and is widely used in topical skincare in the United States, the European Union, and most other jurisdictions. It is not FDA-approved as a drug for any therapeutic indication. FDA previously put injectable / systemic GHK-Cu on the interim Category 2 list for 503A compounding; the agency page current through April 22, 2026 records the nomination as withdrawn and GHK-Cu as no longer in Category 2, but FDA has not stated whether that alters what a pharmacy may compound. While GHK-Cu is not currently listed by name on the WADA Prohibited List, listings change; athletes should consult current WADA documentation directly.